Skip to main content
Lisa M. Ferri

Lisa M. Ferri

T +1 212 506 2340
F +1 212 262 1910
  • RSS Icon

Managing IP 2017 IP Stars

Thirteen Mayer Brown partners were recognized as “IP Stars” in the 2017 edition of Managing Intellectual Property magazine’s “World IP Handbook and Survey,” an annual analysis of the IP market based on extensive research among IP professionals.

IAM Patent 1000

Eighteen of the firm’s Intellectual Property partners are recognized in nine categories in the 2016 edition of the IAM Patent 1000—The World’s Leading Patent Professionals. The recognized lawyers are:

Managing Intellectual Property’s "IP Stars - Top 250 Women in IP"

Lisa M. Ferri is a partner in Mayer Brown’s New York office and co-leader of the firm’s global Intellectual Property practice. She serves as lead trial and appellate counsel for high‐profile companies in the pharmaceutical, biotechnology, and medical device industries. Lisa is a seasoned and versatile litigator, having tried high-stakes cases in federal courts across the country and the International Trade Commission, and argued before the Patent Trial and Appeal Board (PTAB) and the Federal Circuit Court of Appeals. She has significant expertise guiding companies through patent challenges under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA).

Clients and peers alike recognize Lisa as a leading intellectual property lawyer. The New York Law Journal honored her as one of its Distinguished Leaders for 2018. The award is presented to twenty attorneys in leadership roles across the country who have achieved extraordinary results over the past year. Managing Intellectual Property has chosen Lisa as one of the "Top 250 Women in IP" every year since the list’s inception in 2013. Who’s Who Legal: Patents 2016 and 2017 named Lisa as a leading patent litigation lawyer. IAM Patent 1000 called Lisa "spectacular . . . [she] demonstrates a lot of powerful qualities as a patent litigator" and "extremely persuasive." The Legal Media Group named her a "Life Sciences Star" and an "IP Star," noting that "Lisa is professional, intelligent, people savvy, tough when need be, and has a great command of the applicable law." LMG Life Sciences Awards considered Lisa a finalist in 2018 for "New York General Patent Litigator of the Year" and in 2014 for "Hatch‐Waxman Litigator of the Year." In addition, she has been recognized in the area of patent litigation by the Legal 500. LMG Life Sciences Awards shortlisted Lisa’s victory at the Federal Circuit Court of Appeals in Biogen IDEC, Inc. and Genentech v. GlaxoSmithKline, a case involving the monoclonal antibody therapy Arzerra® for "Patent Impact Case of the Year."

Lisa's life sciences practice spans a broad range of therapeutic areas and technologies—from pharmaceuticals and biologics for the treatment of HIV/AIDS, cancer, hepatitis, influenza, auto-immunities, anemia, emesis, and BPH, to drug delivery systems, research tools, recombinant DNA, RNAi and a variety of medical devices. Her pharmaceutical practice focuses on representing innovator companies in cases brought pursuant to the Hatch-Waxman Act. She has successfully defended a number of key blockbuster drugs. Following enactment of the America Invents Act, Lisa handled one of the first co-pending inter partes reviews and district court litigations relating to the Orange Book listed drug Lexiva®—the first "lead compound" IPR to come before the PTAB. Lisa also concentrates on patent litigation dealing with large molecule biologics, including a series of antibody litigations involving the well-known "Cabilly" patent portfolio.

Lisa is an adjunct professor at Fordham University School of Law, where she teaches Patent Litigation.

Lisa serves as co-chair of the firm's global Women's Leadership Committee.

The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.